{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:36Z","timestamp":1753891836765,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>In locally advanced esophageal cancer, the controversy over the two traditional treatment modalities, neoadjuvant radiotherapy and neoadjuvant chemotherapy, has been unending and also challenged by the addition of neoadjuvant immunotherapy. Neoadjuvant immunotherapy has led to an increasing diversity of neoadjuvant combination treatment modalities, among which neoadjuvant immunochemotherapy has emerged, with current clinical studies initially demonstrating its efficacy and safety. We report a case of a patient with locally advanced esophageal cancer who underwent two cycles of neoadjuvant immunochemotherapy and successful surgery and achieved a pathological complete response (pCR). A 73-year-old elderly female patient presented with progressive dysphagia for more than 1 month with an Eastern Cooperative Oncology Group (ECOG) score of 1. After completing gastroscopy + pathological biopsy, chest enhanced CT, barium esophageal meal, PET-CT, and other related examinations, the clinical diagnosis was thoracic segmental esophageal poorly differentiated squamous carcinoma cT2N2M0 stage III. After a multidisciplinary discussion of the comprehensive treatment plan, two cycles of neoadjuvant therapy were given on February 16, 2023, and March 9, 2023, and the treatment plan was as follows: cisplatin 30 mg d1\u20133 + albumin paclitaxel 200 mg d1 and 100 mg d8 + sintilimab 200 mg d4, q3w. After the neoadjuvant therapy, the patient underwent an imaging examination. The chest enhanced CT suggested that the lesion range was significantly reduced compared with the previous scan, and mediastinal lymph nodes were partially reduced. Then, thoracoscopic radical esophageal cancer surgery was performed on April 23, 2023. pCR was achieved by pathological evaluation, and the postoperative diagnosis was thoracic segmental esophageal hypofractionated squamous carcinoma ypT0N0M0. Two cycles of adjuvant immunochemotherapy were performed after surgery on May 30, 2023, and June 21, 2023, and the regimen was as follows: cisplatin 30 mg d1\u20133 + albumin paclitaxel 200 mg d1 and 100 mg d8 + sindilizumab 200 mg d4, q3w. As of the latest review on March 20, 2024, the patient was not seen to have any significant postoperative complications and remains in a state of complete response (CR). Neoadjuvant immunochemotherapy has positive significance for the treatment of patients with locally advanced esophageal cancer. Whether neoadjuvant immunochemotherapy can replace neoadjuvant synchronous radiotherapy is a future direction of research, which needs to be further verified by more reliable clinical trials.<\/jats:p>","DOI":"10.3389\/fonc.2024.1332314","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:40:43Z","timestamp":1720068043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: A case study of neoadjuvant immunochemotherapy for locally advanced esophageal squamous carcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingtong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","article-title":"Esophageal cancer diagnosis and treatment standard (2018 edition)","volume":"9","year":"2019","journal-title":"Chin J Gastroenterol Imaging"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035010","article-title":"Esophageal cancer","volume":"349","author":"Enzinger","year":"2003","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00522-4","article-title":"Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy,and surgery for locoregionally advanced esophageal cancer","volume":"57","author":"Swisher","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00595-019-01878-7","article-title":"Recent progress in multidisciplinary treatment for patients with esophageal cancer","volume":"50","author":"Watanabe","year":"2020","journal-title":"Surg Today"},{"volume-title":"Chinese society of clinical oncology guidelines working committee. chinese society of clinical oncology (csco) guidelines for the treatment of esophageal cancer 2022","year":"2022","author":"Wang","key":"B6"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw010","article-title":"A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastrooesophageal junction","volume":"27","author":"Klevebro","year":"2016","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0133","article-title":"Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma:A randomized clinical trial","volume":"156","author":"Wang","year":"2021","journal-title":"JAMA Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03659-7","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity scorematched study from the national cancer center in China","volume":"148","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nri3197","article-title":"Tumour immunotherapy\u2013leukocytes take up the fight","volume":"12","author":"Alderton","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATT RAC TION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2101983","article-title":"Adjuvant nivolumab in esophageal cancer - a new standard of care","volume":"384","author":"Ilson","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","article-title":"Research progress of neoadjuvant therapy for locally advanced esophageal cancer","volume":"31","author":"Li","year":"2023","journal-title":"Modern Oncol Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17425247.2021.1825376","article-title":"Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action","volume":"18","author":"Xue","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.21037\/atm","article-title":"A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)","volume":"9","author":"Duan","year":"2021","journal-title":"Ann Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12957-021-02446-5","article-title":"Neoadjuvant Camreli-zumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study","volume":"19","author":"Yang","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e003497","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jgo","article-title":"The safety and efficacy ofneoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Shen","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.21037\/atm","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772450","article-title":"The sequence of Chemotherapy and toripalimab might influence the efficacy of neoadjuvant Chemoimmunotherapy in locally advanced esophageal squamous cell cancer-a phase II study","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab011","article-title":"Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma","volume":"27","author":"He","year":"2022","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma(NICE study)","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/jgo","article-title":"Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)","volume":"13","author":"Gao","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant Camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849984","article-title":"Neoadjuvant Pembrolizumab and chemotherapy in resectable esophageal cancer: an open-label,single-arm study (PEN-ICE)","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers11040433","article-title":"Targeting receptor kinases in colorectal cancer","volume":"11","author":"Garc\u00eda-Aranda","year":"2019","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i66","article-title":"Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PDL1 blockade","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.3390\/ijms21176176","article-title":"Resisting resistance to immune checkpoint therapy: a systematic review","volume":"21","author":"Haibe","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12957-019-1712-7","article-title":"Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia","volume":"17","author":"Kuo","year":"2019","journal-title":"World J Surg Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma","volume":"73","author":"Mandard","year":"1994","journal-title":"Clinicopathol correlations Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20916","article-title":"Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation","volume":"103","author":"Chirieac","year":"2005","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1332314\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:40:47Z","timestamp":1720068047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1332314\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":38,"alternative-id":["10.3389\/fonc.2024.1332314"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1332314","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"article-number":"1332314"}}